Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Montpellier – page 77

1 094 clinical trials in Montpellier, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Montpellier at a glance
1 094
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 094 trials in Montpellier

Open in trial search

Diffuse large B-cell lymphoma

Not recruiting

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Non-small cell lung cancer+2

Not recruiting

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Neoplasm malignant

Not recruiting

A Study of GEN1047 in Patients with Solid Tumors: First Time Use in Humans

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gen1047
  • Sponsor:Genmab A/S

Malignant peritoneal neoplasm+2

Not recruiting

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Arrhythmia

Not recruiting

Study on Flecainide to Reduce Risk of Atrial Arrhythmia After Patent Foramen Ovale Closure in Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide
  • Sponsor:Assistance Publique Hopitaux De Paris

Oesophageal carcinoma

Not recruiting

Study of Durvalumab with Chemotherapy and Radiotherapy for Patients with Unresectable Esophageal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Colitis ulcerative

Not recruiting

Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Bronchiectasis

Not recruiting

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

B-cell lymphoma+2

Not recruiting

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lisocabtagene Maraleucel
  • Sponsor:Celgene Corp.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Montpellier

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, bladder cancer, and mantle cell lymphoma. Studies evaluate combination therapies and novel treatment approaches for improved patient outcomes.

  • Advanced HNSCC Treatment Combinations
  • Non-muscle Invasive Bladder Cancer Therapy
  • Gastric Cancer Targeted Treatments

Research includes evaluation of immunotherapy combinations and targeted molecular approaches.

02 Autoimmune Conditions

Studies examining innovative treatments for Crohn's disease, multiple sclerosis, and systemic sclerosis. Research focuses on novel therapeutic approaches and treatment optimization.

  • Fecal Microbiota Transplantation Studies
  • MS Treatment De-escalation Strategies
  • Advanced Autoimmune Therapies

Trials aim to improve disease management and patient quality of life.

03 Rare Diseases

Investigating treatments for achondroplasia, pyruvate dehydrogenase deficiency, and thyroid eye disease. Focus on developing targeted therapies for these uncommon conditions.

  • Growth Disorders in Children
  • Metabolic Disease Management
  • Innovative Therapeutic Approaches

Research aims to address unmet medical needs in rare disease populations.

04 Preventive Medicine

Clinical trials evaluating vaccines for cytomegalovirus, yellow fever, and HPV prevention. Studies focus on immunization effectiveness and safety profiles.

  • Vaccine Development Programs
  • Infection Prevention Strategies
  • Population Health Protection

Research emphasizes disease prevention and public health improvement.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.